HC Wainwright Reaffirms “Buy” Rating for Chimerix (NASDAQ:CMRX)

HC Wainwright restated their buy rating on shares of Chimerix (NASDAQ:CMRX) in a report published on Monday morning,Benzinga reports. HC Wainwright currently has a $11.00 target price on the biopharmaceutical company’s stock.

Several other analysts have also recently commented on CMRX. StockNews.com raised Chimerix from a “sell” rating to a “hold” rating in a report on Wednesday, August 21st. Wedbush reissued an “outperform” rating and issued a $6.00 target price on shares of Chimerix in a report on Thursday, November 7th.

Chimerix Stock Performance

Shares of Chimerix stock opened at $0.90 on Monday. Chimerix has a one year low of $0.75 and a one year high of $1.30. The company has a market cap of $80.83 million, a P/E ratio of -0.96 and a beta of 1.13. The firm has a fifty day moving average of $0.90 and a two-hundred day moving average of $0.91.

Chimerix (NASDAQ:CMRX) last announced its quarterly earnings data on Tuesday, August 13th. The biopharmaceutical company reported ($0.23) EPS for the quarter, meeting analysts’ consensus estimates of ($0.23). The firm had revenue of $0.13 million during the quarter, compared to analyst estimates of $1.26 million. During the same quarter in the previous year, the business earned ($0.21) EPS. As a group, equities analysts predict that Chimerix will post -0.99 earnings per share for the current year.

Institutional Investors Weigh In On Chimerix

Several institutional investors have recently modified their holdings of CMRX. Koshinski Asset Management Inc. purchased a new position in Chimerix in the 1st quarter valued at approximately $42,000. Valeo Financial Advisors LLC increased its position in shares of Chimerix by 566.9% in the third quarter. Valeo Financial Advisors LLC now owns 81,766 shares of the biopharmaceutical company’s stock valued at $76,000 after buying an additional 69,505 shares in the last quarter. Marshall Wace LLP acquired a new position in shares of Chimerix during the 2nd quarter worth $137,000. Connor Clark & Lunn Investment Management Ltd. boosted its position in shares of Chimerix by 66.8% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 344,712 shares of the biopharmaceutical company’s stock worth $321,000 after buying an additional 138,098 shares in the last quarter. Finally, Acadian Asset Management LLC boosted its position in shares of Chimerix by 15.5% in the 1st quarter. Acadian Asset Management LLC now owns 2,174,813 shares of the biopharmaceutical company’s stock worth $2,304,000 after buying an additional 291,981 shares in the last quarter. Hedge funds and other institutional investors own 45.42% of the company’s stock.

Chimerix Company Profile

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.